Latest Funding News

InhaleRx has corrected its quarterly report and revealed a $38.5 million funding deal to fast-track clinical trials for its inhaled therapies targeting breakthrough cancer pain and panic disorder, aiming for FDA approval.

8VI Holdings Limited has confirmed its voluntary delisting from the ASX, reporting a challenging quarter marked by declining cash reserves and a strategic pivot towards preventive care that is yet to yield significant revenue.

Kalamazoo Resources reports robust assay results from its Ashburton Gold Project and secures $1.13 million in capital to fuel ongoing exploration across Western Australia and Victoria.

Kalamazoo Resources Limited reported a $449,000 net cash outflow from operating activities in Q2 2024, maintaining a cautious stance as it explores funding options to sustain its exploration efforts.

Bod Science Limited reports a modest net cash inflow of $51,000 for Q2 FY2025, supported by increased customer receipts and intellectual property sales, while navigating a complex Deed of Company Arrangement and pending acquisition.

Native Mineral Resources secures a conditional $6.5 million investment from entrepreneur Wes Maas, supporting its Queensland gold projects and targeting production restart in Q3 2025.

Phoslock Environmental Technologies reported a widening cashflow deficit and disappointing sales in the December 2024 quarter, while legal challenges and share suspension continue to cloud its outlook.

Patagonia Lithium has withdrawn its previously announced 15-year, 10,000 tonnes per annum production target, clarifying it was aspirational and not compliant with ASX Listing Rules. This retraction raises questions about the project's near-term viability and investor confidence.

Caspin Resources has completed its acquisition of the Bygoo Tin Project in NSW and is set to begin a significant drilling campaign, backed by a recent $1.6 million capital raise.

Ten Sixty Four Limited has received a crucial US$10.5 million payment from Philsaga Mining Corporation, enabling it to settle outstanding related party debts and advance its Deed of Company Arrangement.

Arafura Rare Earths Limited has acknowledged a breach of ASX Listing Rule 15.7 following premature media disclosure of a $200 million investment commitment from the National Reconstruction Fund Corporation. The company outlines corrective steps to prevent future compliance lapses.

Alterity Therapeutics is poised to release topline data from its pivotal ATH434-201 Phase 2 trial in early-stage Multiple System Atrophy by February 2025, while managing a cash balance of A$4.54 million amid ongoing research expenses.